focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Series C Financing

24 Jul 2006 07:02

Amphion Innovations PLC24 July 2006 AMPHION INNOVATIONS PLC PARTNER COMPANY SUPERTRON RAISES $3.5 MILLION IN SERIES C FINANCING July 24 2006 - Amphion Innovations plc today announced that one of its partnercompanies, Supertron Technologies, Inc. a leading developer of next-generationsolutions for high-performance preclinical and clinical Magnetic ResonanceImaging (MRI) coils, probes and accessories, has raised $3.5 million in a SeriesC financing. The round was originally intended to close at $3 million, but the financingincreased due to overwhelming investor demand. As a result of this financing thevalue of Amphion's investment in Supertron will increase from $1.1 million at 31December 2005 to $3.6 million. Amphion's strategy is to invest in and support the growth process of companies,like Supertron, that answer broad-based, unmet market needs with provensolutions and predictable results. Supertron's products dramatically improve theimaging capabilities of conventional MRI scanners. The products greatly enhancethe MRI image quality, reduce scan time in existing scanners and greatly lowerthe cost. These factors ultimately result in earlier disease detection, fasterdrug development, and integrated and/or guided therapeutics. In addition to designing clinical and pre-clinical MRI coils, Supertron is alsodesigning cryogenic coils that increase speed and allow for imaging of bodyparts in motion. The cryogenic coils also improve resolution, which enablesdoctors to see smaller structures. Its solutions are applicable in both high andlow-field clinical, preclinical and research scanning environments. Supertron is also targeting emerging MRI research applications in the fields ofmolecular imaging, image-guided therapeutics, image-guided surgery, andorthopedics imaging. The company is currently developing a number ofnext-generation MRI products in neuro imaging and pre-clinical imaging. Based in Newark, NJ, Supertron has filed four patents and has collaborated inpartnership with Harvard Medical School, Columbia University, StanfordUniversity, University of Medicine and Dentistry of New Jersey, New JerseyInstitute of Technology and University of Queensland, Australia. "We are very pleased that investors and partners recognize the potential inSupertron which is at the forefront of innovations in life sciences," saidRichard C.E. Morgan, Chief Executive Officer of Amphion. "Clearer and fasterMRIs will help doctors detect diseases earlier and it will help researchersdramatically reduce the time it takes to get vitally important new drugs tomarket." The latest round of financing will support product development, intellectualproperty management, critical staffing, marketing, financing fees and costs, andpotential acquisitions. "We are excited by the market response to our offering and the recognition ofthe value of our gateway to improved performance for the magnetic resonanceimaging industry as a whole, which our product and technology set offers," saidC. Richard Hullihen, Chief Executive Officer of Supertron. For more information please contact: Amphion Innovations plcJosh Berkman, Media Relations +1 (646) 747-7158 SupertronCameron Barnard +1 973 639 1112 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert About Supertron Supertron is a market leading developer and manufacturer of superconducting andcryogenically cooled preclinical and clinical MRI coils and accessories.Supertron's gateway technology MRI coils have demonstrated capability ofdramatically increasing speed and resolution of the MRI scanner. Supertron'scoils have been demonstrated at leading medical institutions such as ColumbiaPresbyterian, Brigham and Women's Hospital, Harvard Medical School, DukeUniversity, and overseas at Hong Kong University. On the Web: www.supertron.com About Amphion Innovations plcAmphion Innovations plc is listed on the AIM Exchange in London under the symbolAMP. Amphion develops and operates companies in the life science and medicaltechnology markets, working in partnership with corporations, governments,universities, and entrepreneurs seeking to commercialize their intellectualproperty using its proven company creation and building process. On the Web: www.amphionplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.